| 45.43 Delayed Data As of 3:59pm ET |  +0.02 / +0.04%Today’s Change | 37.43 Today|||52-Week Range 45.62 | +4.65% Year-to-Date |
| Emergent Begins Phase III Study on Anthrax Vaccine AV7909 Mar 20 / Zacks.com - Paid Partner Content | Should Value Investors Consider Sanofi (SNY) Stock Now? Mar 13 / Zacks.com - Paid Partner Content |
| Can Dermira Stock Keep Soaring? Mar 19 / MotleyFool.com - Paid Partner Content | Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion Mar 12 / Zacks.com - Paid Partner Content |
| Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent Mar 18 / Zacks.com - Paid Partner Content | Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps Mar 11 / Zacks.com - Paid Partner Content |
| Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News Mar 13 / Zacks.com - Paid Partner Content |
| Previous close | 45.41 |
| Today’s open | 45.07 |
| Day’s range | 45.07 - 45.49 |
| Volume | 905,184 |
| Average volume (3 months) | 1,019,342 |
| Market cap | $112.5B |
| Earnings growth (last year) | -3.51% |
| Earnings growth (this year) | +4.55% |
| Earnings growth (next 5 years) | +8.14% |
| Revenue growth (last year) | +2.83% |
| P/E ratio | 23.2 |
| Price/Sales | 2.68 |
| Price/Book | 1.67 |
| Today’s change | Today’s % change | |
|---|---|---|
| AZNAstraZeneca | -0.07 | -0.16% |
| GSKGlaxoSmithKline | +0.43 | +1.05% |
| ABBVAbbVie | +0.81 | +1.01% |
| NVONovo Nordisk | +0.33 | +0.63% |
| Next reporting date | April 26, 2019 |
| EPS forecast (this quarter) | $0.78 |
| Annual revenue (last year) | $40.7B |
| Annual profit (last year) | $5.1B |
| Net profit margin | 12.53% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Director Olivier Brandicourt |
Chief Financial Officer & Executive Vice President Jean-Baptiste Chasseloup de Chatillon |
Corporate headquarters Paris, Ile-de-france |
